Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study

• DOI: 10.1016/j.diabres.2025.112017
• Publication Date: 2025-02-01T15:53:56Z
• Authors: Lina Houbachi; Paul Michael Walker; Isabelle Fournel; Elea Ksiazek; Jean-Michel Petit; Alexandre Cochet; Thibault Leclercq; Antoine Roger; Isabelle Simoneau; Benjamin Bouillet; Charles Guenancia
• Keywords: Steatosis; Liver steatosis

We hypothesized that the reduction of intramyocardial fat content may be involved in cardioprotective effect glucagon-like peptide-1 receptor agonists (GLP1-RA) patients with type 2 diabetes (T2D). Therefore, we aimed to evaluate change triglyceride T2D treated GLP1-RA. This monocentric proof-of-concept cohort study included unbalanced prior introduction Patients underwent cardiac magnetic resonance imaging (MRI) coupled nuclear (NMR) spectroscopy at baseline and six months after (M6) a GLP1-RA assess changes levels morphological, functional, tissue parameters. The relative delta (Δr) between M6 was calculated analyzed by Student test or sign test. Twenty-six (mean age = 62.2 ± 6.7 years, median HbA1c 9.1 %) fulfilled inclusion criteria had both NMR measures. Compared baseline, significantly decreased treatment Δr -26 % [95 %CI:-39; -13]p 0.003), as well glycated hemoglobin (HbA1c) (median [IQR:25], p < 0.0001), body mass index (BMI) -6% [-9; -4], 0.0001) left ventricular -6 [-12; -1] 0.02). evolution not correlated (r 0.10) BMI -0.02). demonstrate significant lack correlation reductions suggests specific on myocardial steatosis, which might contribute their previously demonstrated cardiovascular benefits.